Overview
Harton develops a GMP-ready Solid-State Bioprocessing Platform to manufacture cell therapies. It enables production of high-quality therapies with precision, scalability, and efficiency under GMP conditions. The platform uses solid-state bioprocessing to grow and process therapeutic cells with built-in quality controls, allowing consistent, scalable output and reducing costs. Compared with competitors, Harton emphasizes a complete, ready-to-use manufacturing system that standardizes processes and streamlines production, aiming for reliable, reproducible results at scale. The company’s goal is to set the industry standard for cell-therapy manufacturing and ensure that patients in need receive timely access to high-quality treatments.
Work here?Claim your company
Simplify's take
What believers are saying
- Harton raised $15.1 million via SEC Form D on August 14, 2026.
- Its website updated October 16, 2026, expands applications across immune, stem, and engineered cells.
- Metaintro listed two open roles on November 6, 2026, signaling active hiring.
What critics are saying
- Harton still lacks public revenue, customer, or clinical validation.
- A $15.1 million raise funds development, not manufacturing scale or sales force.
- Without a commercial cell-therapy buyer, HT-1 becomes a science project.
What makes Harton unique
- HT-1 combines 3D perfused culture, integrated processing, and automation in one cartridge.
- Harton targets cell therapy manufacturing from R&D through GMP commercial production.
- Its closed, sensor-guided workflows reduce transfers, contamination, and operator variability.
Help us improve and share your feedback! Did you find this helpful?